Titre : Hydralazine

Hydralazine : Questions médicales fréquentes

Nom anglais: Hydralazine

Descriptor UI: D006830

Tree Number: D03.383.710.605.500

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment l'hydralazine est-elle utilisée dans le diagnostic ?

Elle est utilisée pour évaluer la réponse du patient à un traitement antihypertenseur.
Hypertension Antihypertenseurs
#2

Quels tests sont nécessaires avant de prescrire l'hydralazine ?

Des tests de pression artérielle et des analyses sanguines pour évaluer la fonction cardiaque.
Pression artérielle Tests de laboratoire

Symptômes 2

#1

Quels sont les effets secondaires courants de l'hydralazine ?

Les effets secondaires incluent des maux de tête, des palpitations et des éruptions cutanées.
Effets secondaires Maux de tête
#2

L'hydralazine peut-elle provoquer des symptômes allergiques ?

Oui, des réactions allergiques comme des démangeaisons ou un gonflement peuvent survenir.
Réactions allergiques Démangeaisons

Prévention 2

#1

L'hydralazine peut-elle prévenir des maladies cardiaques ?

Elle aide à contrôler l'hypertension, réduisant ainsi le risque de maladies cardiaques.
Maladies cardiaques Prévention
#2

Quelles mesures doivent être prises lors de l'utilisation d'hydralazine ?

Surveiller régulièrement la pression artérielle et signaler tout effet indésirable.
Surveillance Effets indésirables

Traitements 2

#1

Comment l'hydralazine est-elle administrée ?

Elle est généralement administrée par voie orale sous forme de comprimés ou par injection.
Voie orale Injections
#2

Quelle est la posologie standard de l'hydralazine ?

La posologie initiale est souvent de 10 mg à 25 mg, ajustée selon la réponse du patient.
Posologie Ajustement de dose

Complications 2

#1

Quelles complications peuvent survenir avec l'hydralazine ?

Des complications comme la tachycardie ou la rétention hydrique peuvent se produire.
Tachycardie Rétention hydrique
#2

L'hydralazine peut-elle causer des problèmes rénaux ?

Dans de rares cas, elle peut affecter la fonction rénale, nécessitant une surveillance.
Fonction rénale Surveillance

Facteurs de risque 2

#1

Qui devrait éviter l'hydralazine ?

Les patients avec des antécédents de lupus ou de maladies cardiaques doivent être prudents.
Lupus Maladies cardiaques
#2

Quels médicaments interagissent avec l'hydralazine ?

Des médicaments comme les diurétiques et les bêta-bloquants peuvent interagir.
Interactions médicamenteuses Diurétiques
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hydralazine : Questions médicales les plus fréquentes", "headline": "Hydralazine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hydralazine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-12", "dateModified": "2026-04-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hydralazine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Phtalazines", "url": "https://questionsmedicales.fr/mesh/D010793", "about": { "@type": "MedicalCondition", "name": "Phtalazines", "code": { "@type": "MedicalCode", "code": "D010793", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.710.605" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Dihydralazine", "alternateName": "Dihydralazine", "url": "https://questionsmedicales.fr/mesh/D004078", "about": { "@type": "MedicalCondition", "name": "Dihydralazine", "code": { "@type": "MedicalCode", "code": "D004078", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.710.605.500.250" } } } ], "about": { "@type": "MedicalCondition", "name": "Hydralazine", "alternateName": "Hydralazine", "code": { "@type": "MedicalCode", "code": "D006830", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mrigendra B Karmacharya", "url": "https://questionsmedicales.fr/author/Mrigendra%20B%20Karmacharya", "affiliation": { "@type": "Organization", "name": "Ultrasound Research Laboratory, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA, 19104, USA." } }, { "@type": "Person", "name": "Laith R Sultan", "url": "https://questionsmedicales.fr/author/Laith%20R%20Sultan", "affiliation": { "@type": "Organization", "name": "Ultrasound Research Laboratory, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA, 19104, USA." } }, { "@type": "Person", "name": "Chandra M Sehgal", "url": "https://questionsmedicales.fr/author/Chandra%20M%20Sehgal", "affiliation": { "@type": "Organization", "name": "Ultrasound Research Laboratory, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA, 19104, USA. Chandra.Sehgal@pennmedicine.upenn.edu." } }, { "@type": "Person", "name": "Nair Lopes", "url": "https://questionsmedicales.fr/author/Nair%20Lopes", "affiliation": { "@type": "Organization", "name": "Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal." } }, { "@type": "Person", "name": "Mariana Brütt Pacheco", "url": "https://questionsmedicales.fr/author/Mariana%20Br%C3%BCtt%20Pacheco", "affiliation": { "@type": "Organization", "name": "Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine.", "datePublished": "2023-07-14", "url": "https://questionsmedicales.fr/article/37452463", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1756-185X.14809" } }, { "@type": "ScholarlyArticle", "name": "Hydralazine and Hydrazine Derivatives: Properties, Applications, and Repositioning Potential.", "datePublished": "2024-10-21", "url": "https://questionsmedicales.fr/article/39429053", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cbdv.202401561" } }, { "@type": "ScholarlyArticle", "name": "A Rare Case of Hydralazine-Induced Diffuse Alveolar Hemorrhage.", "datePublished": "2023-10-24", "url": "https://questionsmedicales.fr/article/38022102", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7759/cureus.47591" } }, { "@type": "ScholarlyArticle", "name": "Physiologic Treatment of Severe Hypertension in Pregnancy and Postpartum.", "datePublished": "2023-11-30", "url": "https://questionsmedicales.fr/article/38033320", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/AOG.0000000000005472" } }, { "@type": "ScholarlyArticle", "name": "Treatment of acute-onset hypertension in pregnancy: A network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration.", "datePublished": "2023-10-17", "url": "https://questionsmedicales.fr/article/37857042", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.preghy.2023.10.005" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétéromonocycliques", "item": "https://questionsmedicales.fr/mesh/D006573" }, { "@type": "ListItem", "position": 4, "name": "Pyridazines", "item": "https://questionsmedicales.fr/mesh/D011724" }, { "@type": "ListItem", "position": 5, "name": "Phtalazines", "item": "https://questionsmedicales.fr/mesh/D010793" }, { "@type": "ListItem", "position": 6, "name": "Hydralazine", "item": "https://questionsmedicales.fr/mesh/D006830" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hydralazine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hydralazine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2026-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hydralazine", "description": "Comment l'hydralazine est-elle utilisée dans le diagnostic ?\nQuels tests sont nécessaires avant de prescrire l'hydralazine ?", "url": "https://questionsmedicales.fr/mesh/D006830#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hydralazine", "description": "Quels sont les effets secondaires courants de l'hydralazine ?\nL'hydralazine peut-elle provoquer des symptômes allergiques ?", "url": "https://questionsmedicales.fr/mesh/D006830#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hydralazine", "description": "L'hydralazine peut-elle prévenir des maladies cardiaques ?\nQuelles mesures doivent être prises lors de l'utilisation d'hydralazine ?", "url": "https://questionsmedicales.fr/mesh/D006830#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hydralazine", "description": "Comment l'hydralazine est-elle administrée ?\nQuelle est la posologie standard de l'hydralazine ?", "url": "https://questionsmedicales.fr/mesh/D006830#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hydralazine", "description": "Quelles complications peuvent survenir avec l'hydralazine ?\nL'hydralazine peut-elle causer des problèmes rénaux ?", "url": "https://questionsmedicales.fr/mesh/D006830#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hydralazine", "description": "Qui devrait éviter l'hydralazine ?\nQuels médicaments interagissent avec l'hydralazine ?", "url": "https://questionsmedicales.fr/mesh/D006830#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment l'hydralazine est-elle utilisée dans le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elle est utilisée pour évaluer la réponse du patient à un traitement antihypertenseur." } }, { "@type": "Question", "name": "Quels tests sont nécessaires avant de prescrire l'hydralazine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de pression artérielle et des analyses sanguines pour évaluer la fonction cardiaque." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de l'hydralazine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent des maux de tête, des palpitations et des éruptions cutanées." } }, { "@type": "Question", "name": "L'hydralazine peut-elle provoquer des symptômes allergiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des réactions allergiques comme des démangeaisons ou un gonflement peuvent survenir." } }, { "@type": "Question", "name": "L'hydralazine peut-elle prévenir des maladies cardiaques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle aide à contrôler l'hypertension, réduisant ainsi le risque de maladies cardiaques." } }, { "@type": "Question", "name": "Quelles mesures doivent être prises lors de l'utilisation d'hydralazine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Surveiller régulièrement la pression artérielle et signaler tout effet indésirable." } }, { "@type": "Question", "name": "Comment l'hydralazine est-elle administrée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est généralement administrée par voie orale sous forme de comprimés ou par injection." } }, { "@type": "Question", "name": "Quelle est la posologie standard de l'hydralazine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La posologie initiale est souvent de 10 mg à 25 mg, ajustée selon la réponse du patient." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'hydralazine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme la tachycardie ou la rétention hydrique peuvent se produire." } }, { "@type": "Question", "name": "L'hydralazine peut-elle causer des problèmes rénaux ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Dans de rares cas, elle peut affecter la fonction rénale, nécessitant une surveillance." } }, { "@type": "Question", "name": "Qui devrait éviter l'hydralazine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents de lupus ou de maladies cardiaques doivent être prudents." } }, { "@type": "Question", "name": "Quels médicaments interagissent avec l'hydralazine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les diurétiques et les bêta-bloquants peuvent interagir." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale

Validation scientifique effectuée le 03/04/2026

Contenu vérifié selon les dernières recommandations médicales

En savoir plus sur Dr Menir

Sous-catégories

1 au total
└─

Dihydralazine

Dihydralazine D004078 - D03.383.710.605.500.250

Auteurs principaux

Mrigendra B Karmacharya

3 publications dans cette catégorie

Affiliations :
  • Ultrasound Research Laboratory, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA, 19104, USA.
Publications dans "Hydralazine" :

Laith R Sultan

3 publications dans cette catégorie

Affiliations :
  • Ultrasound Research Laboratory, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA, 19104, USA.
Publications dans "Hydralazine" :

Chandra M Sehgal

3 publications dans cette catégorie

Affiliations :
  • Ultrasound Research Laboratory, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA, 19104, USA. Chandra.Sehgal@pennmedicine.upenn.edu.
Publications dans "Hydralazine" :

Nair Lopes

2 publications dans cette catégorie

Affiliations :
  • Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Publications dans "Hydralazine" :

Mariana Brütt Pacheco

2 publications dans cette catégorie

Affiliations :
  • Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Publications dans "Hydralazine" :

Margareta P Correia

2 publications dans cette catégorie

Affiliations :
  • Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
  • Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
Publications dans "Hydralazine" :

Vânia Camilo

2 publications dans cette catégorie

Affiliations :
  • Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Publications dans "Hydralazine" :

Rui Henrique

2 publications dans cette catégorie

Affiliations :
  • Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
  • Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
  • Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Publications dans "Hydralazine" :

Carmen Jerónimo

2 publications dans cette catégorie

Affiliations :
  • Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
  • Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Publications dans "Hydralazine" :

Xuguan Chen

2 publications dans cette catégorie

Affiliations :
  • Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China. Electronic address: chenxg@njmu.edu.cn.
Publications dans "Hydralazine" :

Yong Li

2 publications dans cette catégorie

Affiliations :
  • Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China. Electronic address: liyongmydream@126.com.
Publications dans "Hydralazine" :

Rachel D Crouch

2 publications dans cette catégorie

Affiliations :
  • Department of Pharmacy and Pharmaceutical Sciences, Lipscomb University College of Pharmacy, Nashville, Tennessee (J.P.B., S.M.Y., T.S.T., C.M.G., S.S.P., T.Q.D., R.D.C.); and Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.C.) rachel.crouch@lipscomb.edu.
Publications dans "Hydralazine" :

Satoru Kudose

2 publications dans cette catégorie

Affiliations :
  • Department of Pathology, Columbia University Irving Medical Center, New York, New York, USA.
Publications dans "Hydralazine" :

Maryam Al-Hasani

2 publications dans cette catégorie

Affiliations :
  • Ultrasound Research Lab, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Publications dans "Hydralazine" :

Theodore W Cary

2 publications dans cette catégorie

Affiliations :
  • Department of Radiology, Children's hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Publications dans "Hydralazine" :

Hamidreza Shetabi

2 publications dans cette catégorie

Affiliations :
  • Department of Anesthesiology, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.
Publications dans "Hydralazine" :

David M Charytan

2 publications dans cette catégorie

Affiliations :
  • Nephrology Division, Department of Medicine, NYU Langone Medical Center, New York, New York, USA.
Publications dans "Hydralazine" :

Ting-Ting Chang

2 publications dans cette catégorie

Affiliations :
  • Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC.
Publications dans "Hydralazine" :

Jaw-Wen Chen

2 publications dans cette catégorie

Affiliations :
  • Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC; Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, ROC; Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. Electronic address: jwchen@vghtpe.gov.tw.
Publications dans "Hydralazine" :

Benjamin P Larkin

2 publications dans cette catégorie

Affiliations :
  • Renal Research Laboratory, Royal North Shore Hospital, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
Publications dans "Hydralazine" :

Sources (26 au total)

Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine.

Nov 2023
DOI: 10.1111/1756-185X.14809 PMID: 37452463

We present a case of drug-induced vasculitis secondary to low-dose hydralazine with overlapping features of antineutrophil cytoplasmic antibody-associated vasculitis and drug-induced lupus nephritis.... A 52-year-old Hispanic woman with a medical history of resistant hypertension treated with hydralazine 10 mg twice daily for 1 year presented with generalized weakness, dizziness, nausea, vomiting, an... Although a few cases of simultaneous antibody-associated vasculitis and drug-induced lupus nephritis secondary to hydralazine use have been reported, this case is singular. Similar findings were previ...

Female Humans Middle Aged Lupus Nephritis Hydralazine +5 autres

Treatment of acute-onset hypertension in pregnancy: A network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration.

Dec 2023
DOI: 10.1016/j.preghy.2023.10.005 PMID: 37857042

Consensus on the relative efficacy of available antihypertensive agents used in pregnancy is lacking.... To compare treatment success with antihypertensives and categorize by route of administration.... MEDLINE, Embase, PubMed, Web of Science, Scopus, CINAHL, and clinicaltrials.gov were searched without date restriction.... Peer-reviewed randomized controlled trials (RCTs) comparing pharmacologic agents used to treat hypertension in parturients were included. Evaluated treatment groups included IV-labetalol (BBIV), IV-hy... Seventy-four studies (8324 patients) were eligible post PRISMA guidelines screening. Results were pooled using a Bayesian-approach for success of treatment (study defined target blood pressure), time ... Treatment success (primary outcome, 55 trials with 5518 patients) was analyzed. Surface under the cumulative ranking curve (SUCRA) was categorized for 13 drugs, CCBPO (0.84) followed by CCBSL (0.78) w... Oral calcium-channel blockers ranked highest for treatment success. Ketanserin achieved target blood pressure fastest, warranting additional research. The results should be interpreted with caution as...

Pregnancy Infant, Newborn Female Humans Antihypertensive Agents +9 autres

Hydralazine use can be associated with IgM-dominated immune complex-mediated glomerulonephritis.

29 Apr 2024
DOI: 10.1080/01913123.2024.2346660 PMID: 38685716

IgM-dominant immune complex-mediated glomerulonephritis (IgM-dominant ICMGN) is a rare renal entity, characterized by a membranoproliferative pattern by light microscopy, dominant IgM staining by immu... Seven IgM-dominant ICMGN cases were identified over 8 years. Their pathologic phenotypes and clinical scenarios were analyzed in detail.... Patients' ages ranged from 47 to 87 years old with 5 women and two men. Six of seven patients had drug-induced autoimmune phenomenon (hydralazine-induced positive ANCA and ANA). All of them had renal ... The hydralazine-induced autoimmune phenomenon can be seen in IgM-dominant ICMGN, which should be classified as a subtype of membranoproliferative glomerulonephritis....